Immunovant, Inc.
IMVT · XNASCIK 1764013fmd_13WARN6PRDAVGTBSYQSH0QRD95Manufacturing · Biological Products, (No Diagnostic Substances)Template: Standard
Coverage: Apr 01, 2018 to Sep 30, 2026, 34 periods
Latest annual · FY2026
Millions- Net income
- (506)
- Free cash flow
- (407)
Latest quarter · Q2 FY2027
Millions- Net income
- (97)
Daily close · IMVTIEX trades only
Nov 13, 2025 to Nov 11, 2026 · 250 sessions37.02 USD
Built from trades executed at IEX only, one exchange with a small share of US volume. This is not the consolidated tape. The close is the last IEX trade of the session, not the official closing price. Earlier sessions are divided by the later split ratios the API confirmed against IEX prices; dividends are not adjusted. Switch to As traded for the prices as they printed. End of day, not real time: a session is published the day after it trades.
Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use. iex.io/legal/hist-data-terms
Key stats
Open AnalysisCompound annual growth
- Net income, 5 yearsFY2021 to FY2026
- n/m
Immunovant, Inc. (IMVT) financials: quick answers
Annual figures as filed with the SEC. Each number links to the filing it came from and to its proof.
| Metric | FY2026 | FY2025 | Change | Source |
|---|---|---|---|---|
| Net income | -$505.6 million | -$413.8 million | 10-K 2026-05-20 · proof | |
| Cash from operating activities | -$407.3 million | -$375.9 million | 10-K 2026-05-20 · proof | |
| Free cash flow | -$407.3 million | -$376.6 million | 10-K 2026-05-20 · proof | |
| Total assets | $957 million | $776.2 million | +23.3% | 10-K 2026-05-20 · proof |
| Total liabilities | $104.4 million | $68.8 million | +51.8% | 10-K 2026-05-20 · proof |
| Cash and cash equivalents | $902.1 million | $714 million | +26.4% | 10-K 2026-05-20 · proof |
- What was Immunovant, Inc. (IMVT)'s net income in fiscal 2026?
- Immunovant, Inc. (IMVT) reported net income of -$505.6 million for fiscal 2026 (the year ended Mar 31, 2026), against -$413.8 million the year before. Source: the 10-K filed with the SEC on May 20, 2026. SEC
- What was Immunovant, Inc. (IMVT)'s cash from operating activities in fiscal 2026?
- Immunovant, Inc. (IMVT) reported cash from operating activities of -$407.3 million for fiscal 2026 (the year ended Mar 31, 2026), against -$375.9 million the year before. Source: the 10-K filed with the SEC on May 20, 2026. SEC
- What was Immunovant, Inc. (IMVT)'s free cash flow in fiscal 2026?
- Immunovant, Inc. (IMVT) reported free cash flow of -$407.3 million for fiscal 2026 (the year ended Mar 31, 2026), against -$376.6 million the year before. Source: the 10-K filed with the SEC on May 20, 2026. SEC
- What are Immunovant, Inc. (IMVT)'s total assets?
- As of Mar 31, 2026, Immunovant, Inc. (IMVT) reported total assets of $957 million, against $776.2 million a year earlier (+23.3%). Source: the 10-K filed with the SEC on May 20, 2026. SEC
- What are Immunovant, Inc. (IMVT)'s total liabilities?
- As of Mar 31, 2026, Immunovant, Inc. (IMVT) reported total liabilities of $104.4 million, against $68.8 million a year earlier (+51.8%). Source: the 10-K filed with the SEC on May 20, 2026. SEC
- What are Immunovant, Inc. (IMVT)'s cash and cash equivalents?
- As of Mar 31, 2026, Immunovant, Inc. (IMVT) reported cash and cash equivalents of $902.1 million, against $714 million a year earlier (+26.4%). Source: the 10-K filed with the SEC on May 20, 2026. SEC
Read from the FinancialMD API on Nov 13, 2026. Values change only when a new filing is made; see the Financials tab for every period and as-of replay.
The same numbers for an agent, with proof on every value:
curl "https://api.financial.md/v1/company/financials/income_statement/standardized?company=ticker:IMVT&period_type=annual&limit=5"Information only, not investment advice.